Project description
Innovative technological solution to provide intelligent dosing in ADHD
Attention-deficit hyperactivity disorder (ADHD) is a neurobehavioural disorder with a childhood-onset that combines lack of attention with hyperactivity, impairing multiple aspects of life. Stimulants are primary effective ADHD medications, classified as controlled substances associated with side effects and potential for abuse. They require dose titration throughout the patients’ life. The goal of the EU-funded OnDosis01 project is to develop a therapeutic device that allows effective management of ADHD. This technology will introduce a new way to deliver treatment, integrating medication self-monitoring with intelligent dosing. The integration will simplify dose titration, enabling adherence improvement and reducing risk for medication abuse via tamper resistance.
Objective
The goal of this project is to develop a therapy that allows for more effective management of attention-deficit hyperactivity disorder (ADHD). ADHD is a common, childhood onset, neurobehavioural disorder characterised by a combination of inattention, hyperactivity and impulsivity impairing multiple areas of life. Stimulants are the most widely used ADHD medications and are proven effective on ADHD symptoms, but classified as controlled substances they are associated with concerns about side effects and potential for abuse. In addition, they require careful dose titration at initiation and throughout the patients’ life.
OnDosis aims to address these challenges by developing a novel “combination product”, prescribed as an ADHD treatment regime, that combines a technological platform with stimulant active compounds. This integrated solution will simplify dose titration, enable ease of swallowing, offer adherence support and self-monitoring checks. Importantly, OnDosis’ solution is a personalised device with the potential to reduce risk for medication abuse through tamper resistance and tamper evident features.
The ultimate success of the project will depend on generation of clinical data which will support partnering and out-licensing. OnDosis plans to apply for SMEi Phase 2 grant to take the product through required clinical studies, and then go to market through a licensing agreement with a strong commercial partner. OnDosis has a strong network established with potential pharma partners and investors, and has already gained support from investors that offer strategic support to the company.
The burden of ADHD is increasing and the unmet need is growing. This encourages OnDosis in the endeavour of a needs-driven research to address this widespread challenge. Market research with several stakeholders in healthcare have convinced OnDosis of the potential to bring significant impact to patients with ADHD through this novel technology.
Fields of science
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
431 50 MOLNDAL
Sweden
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.